this population. 1 Therefore, we conducted this analysis to characterize longitudinal suicide rates and ascertain factors associated with suicide among people living with HIV/AIDS who have accessed free HAART in the province of British Columbia.
Methods

Setting
HAART has been provided free-of-charge to people living with HIV/AIDS in BC since its introduction in 1996 through the provincially funded drug treatment program at the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE). The BC-CfE is the centralized distributor of antiretroviral therapy for all patients accessing HIV treatment in BC.
Design
The HAART Observational Medical and Evaluation (HOMER) cohort includes all patients aged 19 years and older who were enrolled at the BC-CfE from 1996 onwards and who began HAART between August 1996 and June 2012. 19 The HOMER protocol was granted ethics approval by the University of British Columbia Research Ethics Board, which approved the retrospective use of anonymous administrative data without requiring consent; an information sheet for participants was provided in lieu of a consent form.
Sources of data
Sociodemographic and clinical data for these patients, including HAART history and immunologic and virologic markers, were available through the BC-CfE treatment registry. Cause and date of death were obtained through an ongoing monthly link between the BC-CfE registry and the British Columbia Ministry of Health Vital Statistics Agency up to June 2012. This link minimizes loss to follow-up to less than 4% and allows all deaths that occurred in the cohort to be included.
Variable selection
Our primary outcome variable was suicide, as listed as the underlying cause of death on the death record from the Vital Statistics Agency. The definition of suicide used in this study was adapted from the Manitoba Centre for Health Policy and includes several poisoning codes, such as "accidental poisoning" that account for International Classification of Disease (ICD)-10 codes suspected of capturing a significant proportion of suicides. 20 The ICD-10 codes from the Vital Statistics Agency used in this definition are listed in Appendix 1 (available at www.cmajopen.ca/content/3/2/E140/suppl/DC1).
The sociodemographic variables evaluated included sex, Aboriginal identity (extracted from several sources, e.g., surveys, physicians' reports and death information), median income (the median income recorded in census data for each patient's postal code was taken as the patient's median income), whether patients were from urban or rural neighbourhoods (determined by postal code information held at the drug treatment program), age at death and year of death. Clinical variables evaluated included diagnosis of an AIDSdefining illness (a condition that, in the setting of an HIV infection, confirms the diagnosis of AIDS. This includes a list of serious and life-threatening diseases such as cancers and infections), a diagnosis of hepatitis C virus (HCV) infection, adherence to HAART treatment in the last year before death, calculated by the number of days undergoing treatment (based on the number of days of coverage provided by a given prescription) divided by the number of days the patient was alive in the last year, the last or most recent HAART regimen, efavirenz as part of the last or most recent regimen, number of years on HAART, most recent and nadir CD4 cell counts and latest viral load. History of injection drug use was the only sociobehavioural variable assessed.
Statistical analysis
Two main analyses were conducted in this study. The first analysis examined the predictors of suicide among all patients in the HOMER cohort who died from suicide or remained alive over the study period, whereas the second analysis was limited to all deaths (suicides and nonsuicides). Statistical comparisons were conducted using the Pearson χ 2 test or Fisher exact test for dichotomous variables and the Wilcoxon rank sum test for continuous variables.
A Cox proportional hazards regression model was used to identify the independent predictors of suicide among patients in the HOMER cohort who remained alive or died from suicide during the study period. Logistic regression was used to identify independent predictors of suicide among suicides and nonsuicides. Variables for inclusion in both models were selected using exploratory model selection process based on Akaike information criterion and type III p values.
Suicide rates and general mortality data in the HOMER cohort were compared with suicide rates and general mortality data in the general population of BC to contextualize findings. These calculations were restricted to 1997-2011 to ensure full-year comparisons. Person-years of risk in the HOMER cohort were based on time under observation of the patient and on annual population estimates in the general population of BC. 21, 22 The number of deaths from suicide in the general population, by year, were obtained from reports of the Vital Statistics Agency. 15 Crude rates were expressed as deaths per 100 000 person-years. The Somers D asymptotic test of trend was used to analyze the change in suicide rates over time because of the small number of deaths due to suicide.
Results
Our analysis involved 5229 people living with HIV/AIDS in the HOMER cohort who began HAART between August 1996 and June 2012 in BC. A total of 82 deaths from suicide were observed. Figure 1 shows the decline in suicide rates during our study period from 961 deaths per 100 000 personyears in 1998 to 2.81 deaths per 100 000 person-years in 2010 (the last year any suicides were recorded in this cohort). A test for trend showed this decline was statistically significant (p < 0.001). A relatively constant suicide rate in the general population of BC was observed; similarly, the proportion of suicide deaths among all-cause mortality deaths was constant over time. Table 1 provides the ICD-10 codes for the deaths due to suicide (n = 82).
The bivariate analysis in Table 2 describes the characteristics of all study participants who died from suicide (n = 82) compared with those who remained alive (n = 4236), but excludes those patients who died of causes other than suicide (n = 911). Seventy-eight percent of individuals who died from suicide were male, the median age was 42 years and the median number of years on HAART was 3. Ethnicity (p = 0.013), annual income (p = 0.012), injection drug use (p < 0.001), HCV status (p < 0.001), most recent HAART regimen or last HAART regimen before death (p = 0.002), efavirenz included in the last or most recent HAART regimen (p = 0.002), and never having had an AIDS-defining illness (p = 0.0011) were associated with suicide. Younger age (p < 0.001), poor treatment adherence in the last or most recent year preceding death (p < 0.001), higher baseline CD4 cell count (p = 0.001), lower last or most recent CD4 cell count (p < 0.001), and higher last or most recent viral load (p < 0.001) were also significantly associated with suicide.
A second bivariate analysis ( Table 3 ) was performed to compare suicide deaths (n = 82) to nonsuicide deaths (n = 911). Younger age of death (p = < 0.001), death in an earlier calendar period (earlier in the HAART era) (p < 0.001), and higher nadir, baseline and most recent CD4 cell counts before death (p < 0.001) were associated with suicide. Never having had an AIDS-defining illness (p < 0.001) and HCV status (p = 0.013) were also significantly associated with suicide. Table 4 highlights the results of the Cox proportional hazards model. In this analysis, those patients who died from nonsuicide deaths were censored, and never having had an AIDS-defining illness (adjusted hazard ratio [AHR] 4.45, 95% confidence interval [CI] 1.62-12.25) or having a history of injection drug use (AHR 3.95, 95% CI 1.99-7.86) were independently associated with an increased rate of suicide mortality. Each additional calendar year was associated with a 51% decrease in suicide rate (AHR 0.49, 95% CI 0.45-0.54). Table 5 highlights results from the logistic regression model comparing suicide with nonsuicide deaths. Never having an AIDS-defining illness was associated with nearly a 7-fold 
Interpretation
Our results show that suicide rates among patients using HAART have declined substantially since the start of the HAART era. However, suicide rates remained elevated compared with the general population. Suicide mortality decreased with each calendar year during the HAART era and was greater among those patients who never experienced advanced HIV disease in the form of an AIDS-defining illness. Several factors may have contributed to such a dramatic decline within this cohort. First, as the HAART era progressed, treatment regimens became simpler, more effective, less toxic and better tolerated, 18 ,23 thereby reducing treatment burden and impact on quality of life. Second, HIV was initially characterized as a terminal illness, and therefore inherently associated with an elevated risk of suicide, 18, 24 but HAART transformed HIV into a chronic manageable condition. 9, 23 Third, public perception of HIV has evolved over time, leading to greater social acceptance of people living with HIV/AIDS and potentially contributing to reduced suicide rates in this population. People living with HIV/AIDS in BC may now be less exposed to established correlates of suicidality, such as stigma, marginalization and social exclusion, 9, 15, [17] [18] [19] [20] [21] than at the start of the epidemic. Finally, improved access to facilities (e.g., the supervised injection site) may have reduced the number of accidental poisonings and improved access to psychiatric care may have helped to mitigate suicide behaviour, including suicidal thoughts, ideation and attempts, and prevent escalation to the most severe end of the spectrum, death by suicide.
Consistent with previous research, injection drug use was independently associated with higher rates of suicide mortality. 17, 25, 26 Within the HOMER cohort, over a third of participants had a history of injection drug use, a behaviour known to often occur in the presence of concomitant mental illness, 27, 28 and psychosocial and socioeconomic disparities. 25, 29 It may be that compromised mental health becomes neglected in the face of injection drug use, HIV infection and more visibly apparent health concerns, therefore contributing to the exacerbation of suicide risk or suicidality. 16, 18, 30 Moreover, even though mental health services have always been offered free of charge in BC as part of the public health care system, the need for specialized services for patients with HIV infection was recognized early on in the epidemic. Designated psychiatrists have provided care at the John Ruedy Immunodeficiency Clinic at St. Paul's Hospital, Vancouver, since 2003. This clinic provides outpatient care for patients with HIV infection who have significant comorbidities; subsequently, the mental health services team expanded to include psychiatric nurses, social workers, counsellors and psychologists. There are other outpatient psychiatric services throughout the province that are free-of-charge for BC residents, but they are not exclusively for patients with HIV infection. These services may help mitigate suicide behaviour, including suicidal thoughts, ideation, and attempts, and prevent escalation to the most severe end of the spectrum, death by suicide. Recent research reported an association between regimens containing efavirenz and an increased risk of suicidality. 31 Our analysis only detected an association between suicide and efavirenz in univariate results comparing those patients who died of suicide to those who remained alive. However, the small number of suicides in our sample and the small number of these patients who were prescribed efavirenz in their most recent regimen limited our statistical power. Moreover, most of the suicides in the HOMER cohort occurred earlier in the HAART era (between 1996 and 2004), a time when nevirapine was the primary nonnucleoside reverse-transcriptase inhibitor prescribed.
Conflicting results have been reported with respect to the relationship between disease stage and suicide. 5 studies reported that advanced HIV disease is associated with a greater likelihood of suicide, 6, 18, 34 whereas others reported that disease progression or symptomatic disease is not associated with an increased risk of suicide. 17, 18, [35] [36] [37] Our results showed that those patients who never had an AIDS-defining illness were more likely to die by suicide, which is consistent with a previous finding that 70% of the autopsies in patients with HIV infection who died by suicide showed no signs of AIDS-related disease. 17 This suggests that people living with HIV/AIDS with less graduated disease are at greater risk of suicide. Within our No. of years of treatment with HAART, yr; median (IQR) 3 (2-6) 6 (3-10) < 0.001
Note: HAART = highly active antiretroviral therapy, IIN = integrase inhibitor, IQR = interquartile range, NNRTI = non-nucleoside reverse-transcriptase inhibitor, PI = protease inhibitor. *Unless otherwise specified. †End of follow-up can be the date of death, the date of last contact, date of last contact before moving out of British Columbia or to participation in antiretroviral blinded trials. ‡Some values for income were missing. Median income was calculated using n = 65. §Some values for income were missing. Median income was calculated using n = 3308. Readers should be cautious when interpreting our results. First, in the cross-sectional analysis, we were able to highlight associations, but unable to show or infer causality or direction of the associations. Second, our data pertained to a very specific population of people living with HIV/AIDS who have started HAART in BC, which is a universal health care setting with free access to treatment and HIV-related care. Third, the lack of accepted methodology within this field of research, suicidality in HIV-positive populations, limits the comparability and generalizability of results across studies. 1, 9, 11, 41, 42 Fourth, suicides may be underestimated as those that occur as a result of selfadministered withdrawal of care or similar indirect ways often cannot be distinguished as such; however, given the definition of suicide used in this study includes accidental poisoning it may also be possible that the number of suicides was overestimated and that some instances of overdose death are, in fact, not suicides. Fifth, our sample size, information on certain variables such as injection drug use and sex distribution is limited; in addition, we had no access to clinical information regarding previous psychiatric history, particularly depression, or any mental health-related treatments. Lastly, suicide itself can be seen as the severest outcome of a spectrum. We did not collect data for other suicidal or self-harming behaviours, but we acknowledge that they are closely related because they represent the array of suicidal behaviours that exist.
Conclusion
Suicide rates among patients with HIV infection who access antiretroviral therapy have declined substantially since 1996. Our results reflect a large decline in the number of suicides compared with other recent studies, such as those reported by the national registries of Switzerland and Denmark. This difference is likely partially due to differences in methodological design  HOMER is a distinct cohort of patients living with HIV who are receiving treatment  and we have a centralized distribution site in which all patients who are receiving treatment in BC are enrolled. However, despite substantial declines, suicide rates in our cohort remained at nearly 3 times the rate of the general population in the most recent comparison. Thus, our results reinforce the need for further integration of care, and proactive mental health screening and treatment in patients with HIV infection, particularly for those with histories of injection drug use, to identify suicidal risk.
